News und Analysen

If you're trying to build a passive income stream to eventually fuel your dream retirement, Abbott Laboratories (NYSE: ABT) is a stock you probably want to know more about. This legendary dividend

Shares of Insmed (NASDAQ: INSM) were soaring 17.1% higher as of 11:27 a.m. ET on Tuesday. The big gain came after the company announced positive top-line results from its late-stage Arise clinical

Unlike many of its big pharma peers, Eli Lilly (NYSE: LLY) is a growth stock that's likely to maintain a faster-than-average pace of expansion over the next few years. Between its massive portfolio

Though the pandemic isn't over, people haven't been rushing out to get coronavirus vaccines these days. This spring, the international public health emergency came to an end, and it looked as if we

Many investors are having a hard time finding good reasons to invest in Pfizer (NYSE: PFE) right now, at least if we go by the company's performance in the stock market this year. Pfizer's shares

On Aug. 23, CVS Health (NYSE: CVS) made waves when it announced that it will be launching a new business called Cordavis that will be devoted to commercializing biosimilar medicines. If you aren't

As a growth investor, few signs are as encouraging to witness from one of your holdings as a rapidly growing customer base. This is because such an occurrence typically means that the revenue of a

When's a good time to invest in dividend stocks? Any month that has a vowel in its name. 

We asked three Motley Fool contributors to identify no-brainer dividend stocks to buy in September. Here's

The aim of growth investing is to build significant wealth. Targeting companies that are briskly growing revenue can be a lucrative approach to investing.

In the past five years, the genetic

Catalent (NYSE: CTLT) is one company that probably wishes the summer would never end. As August came to a close, the contract drug manufacturer's stock enjoyed a nearly 12% rise over the course of

There is some good news and bad news for fans of Cathie Wood. The good news for the co-founder CEO of the Ark Invest family of exchange-traded funds (ETFs) is that her largest fund -- with more than

On Aug. 23, CVS Health (NYSE: CVS) announced that it's launching a new subsidiary focused on biosimilar drugs. That business, Cordavis, will start by seeking to commercialize a biosimilar to

Every quarter, investors get excited for companies to report earnings. Some want the updated numbers that management teams share. Others are more curious to hear about plans and projections

If you consider yourself a dividend investor, asking yourself the following question may aid in your success: What separates the wheat from the chaff among dividend stocks? Such a question gets you

Pfizer (NYSE: PFE) offered investors certainty in the earlier stages of the pandemic. People were clamoring for coronavirus vaccines and treatments, and Pfizer became a leader in both markets. Its

Shares of Novocure (NASDAQ: NVCR) are down 25.9% so far this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence, as the company announced a

Concerns around COVID-19 are diminishing but they are not going away entirely. New variants are emerging and case numbers have been climbing.

One company that continues to work on developing an

Are you a biotech investor who feels left behind? You're not alone. The broad Nasdaq Composite index has gained 13.7% since mid-May, but the Nasdaq Biotechnology index fell slightly over the same

Medical device maker Insulet's (NASDAQ: PODD) stock was the cure for the investor blues on Wednesday. Following news of a large insider buy, the shares subsequently shot more than 6% higher on the

Shares of Patterson Companies (NASDAQ: PDCO) fell as much as 14.2% early Wednesday, then partially recovered to trade down 5.6% as of 11.50 a.m. EDT after the company announced slightly

Investing in stocks isn't just for the rich and famous since quality stocks can be found at almost any price. Some are trading for well above $1,000 per share, while others go for less than $100

Contract drug manufacturer Catalent (NYSE: CTLT) provided some very effective medicine to its investors on Tuesday. The company's shares leaped almost 5% higher following the publication of its

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. Both companies are among the leaders in the biotech industry. Both have deep lineups and pipelines. And both are looking to

While government programs help retirees replace some of their income once they stop working, these initiatives aren't meant to fund all of people's expenses in their golden years. That's why many

The latest rise in COVID-19 statistics is bringing investors back to coronavirus stocks. That, combined with a top-down effort to develop an updated vaccine and get it in the arms of as many